Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Iovance Biotherapeutics (IOVA) EBIAT (2016 - 2025)

Iovance Biotherapeutics has reported EBIAT over the past 13 years, most recently at -$71.9 million for Q4 2025.

  • Quarterly results put EBIAT at -$71.9 million for Q4 2025, up 8.5% from a year ago — trailing twelve months through Dec 2025 was -$391.0 million (down 5.04% YoY), and the annual figure for FY2025 was -$391.0 million, down 5.05%.
  • EBIAT for Q4 2025 was -$71.9 million at Iovance Biotherapeutics, up from -$91.3 million in the prior quarter.
  • Over the last five years, EBIAT for IOVA hit a ceiling of -$71.9 million in Q4 2025 and a floor of -$116.4 million in Q4 2023.
  • Median EBIAT over the past 3 years was -$106.9 million (2023), compared with a mean of -$100.6 million.
  • Biggest five-year swings in EBIAT: soared 32.5% in 2024 and later dropped 14.99% in 2025.
  • Iovance Biotherapeutics' EBIAT stood at -$116.4 million in 2023, then soared by 32.5% to -$78.6 million in 2024, then grew by 8.5% to -$71.9 million in 2025.
  • The last three reported values for EBIAT were -$71.9 million (Q4 2025), -$91.3 million (Q3 2025), and -$111.7 million (Q2 2025) per Business Quant data.